MEDI4736 is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody directed against human programmed death ligand 1 (PD-L1). MEDI4736 blocks inhibitory interaction of PD-L1 with the PD-1 (CD279) and B7-1 (CD80) molecules, and enhances T-cell activation.
The primary objectives of the analysis presented by Falman and colleagues (ASCO 2014; Abstract 2602) were to assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MEDI4736 in patients with advanced solid tumors, including non-small-cell lung cancer, melanoma, head and neck, pancreatic, gastroesophageal, triple-negative breast cancer, and hepatocellular carcinoma. This phase 1 study is evaluating the safety, tolerability, and PK of MEDI4736 given at doses of 0.1, 0.3, 1.0, 3.0, and 10 mg/kg every 2 weeks, as well as 15 mg/kg every 3 weeks (Figure).
A total of 38 patients provided evaluable data for the PK assessment. PK parameters, including peak concentration (Cmax) and area under the concentration-time curve from 0 to 14 days (AUC [0-14]), were estimated after the first dose of MEDI4736. Cmax increased in an approximately dose-proportional manner over the dose range tested. In contrast, AUC [0-14] increased in a greater than dose-proportional manner that approached linearity at doses of 3 mg/kg every 2 weeks and higher, suggesting that MEDI4736 exhibits nonlinear PK. Researchers hypothesized that this may be due to saturable target-mediated clearance.
Their analysis of the PD of MEDI4736 showed concentration-dependent target engagement as demonstrated by suppression of serum PD-L1. To date, no immunogenicity has been noted at the dose of 10 mg/kg every 2 weeks.
Falman and colleagues concluded that the 10-mg/kg dose of MED4736 is expected to yield concentrations that fully suppress PD-L1 throughout the dosing interval. It is this dose of MEDI4736 that is currently being evaluated in multiple trials of solid tumors.
Learn more about our family of publications.
View Our Publications